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ABSTRACT
The pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become the reason of the 
global health crisis. Since the first case of diagnosed COVID-19 pneumonia was reported in Wuhan, Hubei Province, China, 
in December 2019, the infection has spread rapidly to all over the world. 
The knowledge gained from previous human coronavirus infection outbreaks suggests that pregnant women and their 
foetuses represent a high-risk population during infectious disease epidemics.
Moreover, a pregnancy, due to the physiological changes involving immune and cardiopulmonary systems, is a state 
predisposing women to respiratory complications of viral infection.
The constantly increasing number of publications regarding the course of COVID-19 infection in pregnant women has been 
published, however, the available data remains limited and many questions remain unanswered. The aim of this review 
was to summarize the literature data and adjusted to current recommendations regarding pregnancy care, delivery and 
postpartum period. 
An extremely important issue is the need to register all the cases of COVID-19 affected women and the course of these 
pregnancies to local, regional, or international registries, which will be helpful to answer many clinical and scientific questions 
and to create guidelines ensuring an adequate level of care for women affected by COVID-19 infection during pregnancy, 
delivery and during postpartum period, as well as their newborns.
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INTRODUCTION
Coronaviruses are a group of RNA viruses which are 
one of the largest RNA viruses in terms of the genome 
(~ 30,000 nucleotides) and virus size (spherical, 80–180 nm in 
diameter). Their name derived from the glycoprotein spikes 
of the coronavirus double-layer nucleocapsid, which creates 
an image of the corona in the electron microscope [1, 2].
Until the end of the 20th century, known coronaviruses 
infected people much less frequently, causing infections 
mainly in animals, being an etiological factor in the inci-
dence of birds, cats, dogs, pigs, mice, horses, whales, camels 
and bats [3].
Human Coronavirus (HCoV), known as aetiologi-
cal factors of about 15–30% of mild, seasonal infections 
of the lower and upper respiratory tract, can also cause 
gastrointestinal and rarely found nervous system infec-
tions. Thus far, eight human-infecting coronaviruses are 
known: HCoV-229E, HCoV-OC43, HCoV-NL63, HCoV-HKU1, 
HCoV-SARS, HCoV-MERS and SARS-CoV-2, the last five of 
which were described in the 21st century [4, 5]. Coronavi-
ruses have one of the largest genomes among RNA viruses, 
which, combined with the high variability characteristic of 
RNA viruses, leads to the accumulation of genome sequence 
changes, which can result in the formation of different virus 
variants and a change in cellular tropism [6].
The first reports of human coronaviruses originated 
during the 1960s when two pathogens - HCoV-229E and 
HCoV-OC43 — were isolated and described — causing 
respiratory diseases in humans [7]. For over 40 years they 
were the only representatives of the Coronaviruses with 
the capability of causing infections in humans. The image 
of human coronaviruses as relatively harmless pathogens 
changed with the emergence of the new highly infectious 
human coronavirus species in the Chinese province of 
Guangdong in November 2002 — the SARS-CoV virus, which 
causes severe acute respiratory syndrome (SARS) [8, 9]. 
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During one season, the virus spread to 37 countries, 
8273 cases of infection were found, of which 775 were fatal 
[10]. The MERS-CoV virus (Middle East Respiratory Syndrome 
Coronavirus) was first isolated in a patient from Saudi Arabia 
in 2012 [3]. By July 2017, 2040 infections were recorded, of 
which 712 were fatal [11].
The first cases of COVID-19 were recorded in the city of 
Wuhan with a population of over 11 million, the capital of 
the Hubei Province (60 million inhabitants) in Central China, 
at the beginning of December 2019. The location, transport 
and logistics, conducive to migration of infected people, 
have enabled the extremely rapid spread of the virus across 
all continents [12].
According to ECDC (European Center for Disease Preven-
tion and Control) data, between December 31, 2019, and 
July 9, 2020, there were 12 017 118 cases of infection found, 
of which 549 6276 were fatal [13].
Comparison of genetic materials of coronavirus known 
to date indicates that SARS-CoV-2 is most likely a mutated 
bat-borne coronavirus that is often the asymptomatic carrier 
of many coronavirus species [14]. SARS-CoV-2 coronavirus 
has obtained human-to-human transmission ability through 
mutations. Its genome is 80% identical to the genome of the 
SARS-CoV-1 virus and 50% identical to the MERS-CoV [15].
Particular coronaviruses use different cell receptors, 
which was used to divide them into three groups — de-
pending on which receptor they recognize. The viruses be-
longing to group 2, which includes the SARS CoV virus, use 
human angiotensin 2 convertase [4]. HACE2 receptors are 
found on cells of many human tissues, but the strongest ex-
pression of these receptors occurs in the lungs and kidneys 
[16]. Protein molecules are located in the outer shell of the 
SARS-CoV-2 virus, which specifically binds to angiotensin 
2 converting enzyme present on the surface of the airway 
epithelial cells and alveoli. The number of ACE2 receptors is 
characterized by individual variability — there are 3.5 times 
fewer receptors in alveoli in women than in men, which may 
explain the differences in COVID-19 in both sexes [17, 18].
Transmission of SARS-CoV-2 virus between people is 
mainly via a droplet route through a carrier, which is an aero-
sol and microdroplets emitted from the respiratory tract of 
an infected person containing replicated viruses. Infection 
can also occur through contact with the patient’s secretions, 
the virus is not absorbed through the skin, but it can be 
involuntarily transmitted to the mucosa or conjunctiva. 
The presence of SARS-CoV-2 RNA in feces, urine and — in 
the case of severe infections — the blood of patients [19]. 
Although isolation of live virus is possible from faeces in 
some patients, according to a joint WHO-China report, the 
transmission of faecal-oral infection does not appear to be 
particularly important in the spread of infection [20]. Unlike 
other droplet-transmitted RNA viruses, such as Zika virus 
(ZIKV) [21] or Ebola virus (EBOV) [22], SARS CoV 2 virus has 
not been found in vaginal secretions in women [23, 24].
The current, constantly deteriorating epidemiological 
situation worldwide, forces ongoing review of existing rec-
ommendations regarding pregnancy care, delivery and after 
postpartum period, considering obstetric knowledge and 
experience as well as an individual approach to the patient.
Some physiological changes occurring during pregnan-
cy may increase the susceptibility of the pregnant woman to 
infections. Anatomical changes, such as an increase in the 
transverse dimension of the chest and an increase in the 
height at which the diaphragm is located, are factors re-
ducing the tolerance of a pregnant woman to hypoxia [25]. 
Dyspnoea is a symptom affecting approximately 18% of 
patients with confirmed COVID-19. However, it should be re-
membered, that during pregnancy physiological shortness 
of breath is caused by increased maternal oxygen demand 
due to increased metabolism and oxygen consumption by 
the fetus, which requires differentiation from pathological 
dyspnoea as a manifestation of the disease [26]. Changes 
in lung volume and vasodilatation can lead to swelling of 
the mucosa and increased secretion in the upper respira-
tory tract. Also, changes in the immune system in relation to 
cellular immunity contribute to an increased susceptibility 
of pregnant women to infections caused by viruses [27]. 
Concerning the fetus and newborn, the immaturity of the 
immune system makes it highly prone to infections. It is 
particularly important to determine whether a given infec-
tious agent can infect the fetus or newborn through vertical 
transmission.
Therefore, pregnant women and newborns should 
be assessed as potential risk groups in the current COV-
ID-19 pandemic.
MATERIAL
The knowledge about coronavirus infection during 
pregnancy is limited. It is partly based on the experience of 
the SARS and MERS epidemics, which indicate that infection 
with these viruses may result in adverse clinical outcomes, 
including life-threatening maternal disease, which in some 
cases requires hospitalization, intensive care, and ventila-
tion support. SARS and MERS infections can lead to death 
of pregnant women, but no specific risk factors for death 
during pregnancy have been identified [28].
The current review of data obtained from all published 
reports on pregnancy and neonatal results in women with 
confirmed COVID-19 is available in the Cochrane Gynecol-
ogy and Fertility Group [29].
In general, although the data on pregnancy outcomes 
are reassuring, they should be interpreted with caution. 
Besides, due to the duration of the pandemic, these reports 
mainly relate to infections in the third trimester of preg-
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nancy. So far, no information is available on the possible 
impact of COVID-19 infection on the development of the 
first trimester of pregnancy, as well as no studies on the 
potential teratogenic effect on embryo-fetal development.
The collection of this information is carried out on an on-
going basis, taking the form of a wide-ranging study, e.g. 
the prospective ASPIRE (Assessing the Safety of Pregnancy 
In the Coronavirus Pandemic) cohort study is conducted in 
the United States, covering women who have become preg-
nant naturally or through assisted reproduction methods in 
the period from December 31, 2019, to March 1, 2020, or 
global reports on individual cases of pregnancies obtained 
as a result of assisted reproduction methods in women with 
confirmed infection collected by the European Society of 
Reproduction and Embryology [30].
In the initial period of the pandemic, the American Socie-
ty for Reproductive Medicine (ASRM) and the European Soci-
ety for Reproduction and Embryology (ESHRE) independent-
ly presented their opinion in which it was recommended 
to stop reproductive care, except in the most urgent cases 
[31, 32]. Recently, thanks to effective strategies to limit the 
spread of COVID-19 infections in some areas, gradual re-
sumption of full reproductive care has begun. In a document 
of May 29, 2020, ASRM, ESHRE and the International Federa-
tion of Fertility Societies (IFFS) jointly confirmed the opinion 
emphasizing the importance of continuing reproductive 
care during the COVID-19 pandemic. Besides, ASRM, ESHRE 
and IFFS work together to support patients and collect data 
and resources to better understand COVID-19 regarding 
reproduction, pregnancy, and fetal and neonatal effects [33].
The basis for current guidelines in force in Poland are 
the joint recommendations published on March 16, 2020, 
regarding the treatment of infertility of the Polish Soci-
ety of Reproductive Medicine and Embryology (PTMRiE), 
the Fertility and Infertility Section of the Polish Society of 
Gynecologists and Obstetricians (PTGiP) and the National 
Consultant in the field of Gynecological Endocrinology and 
reproduction.
According to these recommendations, in the case of 
patients undergoing medically assisted procreation (ART) 
treatment, if they are at risk (i.e. who have been in places 
with a high incidence rate, were in contact with an infected 
person, are suspected of being infected COVID-19 or exhibit 
symptoms of inflammation of the upper respiratory tract), 
depending on the stage of therapy, it is recommended to 
stop or postpone the treatment and use the procedure of 
freezing oocytes or freezing embryos. If patients undergoing 
therapy are not at risk and are healthy, it is recommended to 
complete initiated infertility treatment procedures with pos-
sible consideration of deferment of the transfer. When using 
immunomodulatory therapies, if for any reason they are 
used in addition to infertility treatment, it is recommended 
to stop them, because in the period of the epidemic threat it 
can be a serious threat to health and life. Pregnant women 
and patients undergoing treatment or planning treatment 
should strictly avoid contact with infected people, those 
who are undergoing quarantine and avoid places where 
the risk of infection is increased.
All patients trying to conceive, those who are planning 
infertility treatment and those who are undergoing treat-
ment, even if they do not meet the diagnostic criteria for 
COVID-19 infection, are advised to take precautions during 
therapy or postpone the treatment (limited to freezing of 
oocytes or embryos) [34].
There are currently no data that would indicate an increased 
risk of miscarriage in patients infected with SARS CoV-2. Stud-
ies in early pregnancy in women infected with SARS-CoV and 
MERS-CoV also showed no significant association between 
infection and an increased risk of miscarriage [35].
There have been several systematic reviews in recent 
weeks regarding the course of COVID-19 infection in preg-
nant women. Zaigham et al. in a systematic review of 18 pa-
pers refer to 108 pregnant women hospitalized mainly in 
China, as well as from the USA, Sweden, Korea and Honduras, 
in whom COVID-19 infection was confirmed by PCR between 
December 2019 and April 2020. The average age of infected 
pregnant women was 29–32 years, most of the infections 
occurred in the third trimester. Only 22 women were in 
early pregnancy and were discharged without significant 
complications, with preserved pregnancy. Additional risk 
factors were found in pregnant women like chronic diseases 
or pregnancy complications, such as gestational diabetes, 
hypertension, preeclampsia and hypothyroidism [36]. Re-
garding the clinical course of COVID-19 infection, in most 
cases, the disease usually begins with fever, fatigue and dry 
cough. The less common symptoms include shortness of 
breath and tachypnoea, rhinitis, sore throat, hemoptysis, 
shortness of breath, headaches, and more rarely diarrhoea. 
According to the literature data, about 20% of patients 
have symptoms of interstitial pneumonia causing respira-
tory failure of varying severity, which requires mechanical 
ventilation in 3% of cases [15].
Symptoms in pregnant women may be nonspecific, be-
sides, the asymptomatic course is often observed. Zaigham 
et al. report that fever (68%) and dry cough (34%) domi-
nated among the clinical symptoms presented by pregnant 
women at the time of admission to the hospital. Fatigue 
(13%), shortness of breath (12%) and diarrhoea (6%) were 
less frequently observed symptoms. Additional laboratory 
tests showed lymphocytopenia (59%) and increased levels 
of C-reactive protein (70%). As far as the pregnancy outcome 
is concerned 92% of women gave birth by caesarean sec-
tion, 7 out of 85 women had a vaginal birth. There were no 
deaths among women in this group [36].
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In the group of 43 pregnant women described by Bres-
lin et al. with confirmed infection, 29 (67.4%) manifested 
symptoms of infection while admitted to the hospital. 
Dry cough (65%), fever (48%) and myalgia (38%) were the 
most common among the reported symptoms. Less com-
mon symptoms included: headache (27%), shortness of 
breath (24%), and chest pain (17%). Twenty-five women in 
this group (86.2%) did not require oxygen therapy or ad-
ditional treatment and were discharged home in a stable 
condition. In the remaining four patients, the condition 
deteriorated, which was manifested by fever and increased 
respiratory effort, and the need for respiratory support and 
additional treatment. In one pregnant woman, an X-ray 
examination confirmed severe interstitial pneumonia and 
required admission to the ICU. The remaining 14 women 
did not present signs of infection at admission, 12 of them 
remained asymptomatic throughout the infection [37]. 
Breslin et al. noted in this group 2 cases of patients requir-
ing hospitalization in ICU conditions. These women were 
found to have comorbidities and/or pregnancy complica-
tions such as pre-existing type 2 diabetes, poorly controlled 
gestational diabetes, gestational hypertension, gestational 
cholestasis, asthma, and BMI above 35 kg/m2. Both patients 
delivered by caesarean section due to failure of progress or 
failed induction of delivery. In one patient, the surgery was 
complicated by uterine atony and perinatal haemorrhage. 
A second patient experienced respiratory failure 25 hours 
after cesarean section. On the fifth day after surgery, she still 
required oxygen therapy, and she developed acute obstetric 
kidney injury [38].
The effect of COVID-19 infection did not demonstrate 
as a cause of foetal growth restriction [39]. The presence 
of placental pathologies found after delivery of women 
infected with SARS [40] has not been confirmed.
Regarding infant mortality, Zhu et al. reported one case 
of neonatal death and six cases of neonates requiring admis-
sion to the Neonatal Intensive Care Unit. A symptom that 
occurred in all the described newborns was shortness of 
breath. Also, some of them had a fever, thrombocytopenia, 
liver dysfunction, tachycardia and vomiting. The neonatal 
death case concerned a premature newborn born at the 
34th week of pregnancy, the result of a throat swab for 
SARS-CoV 2 performed on the ninth day of life was negative. 
As factors that contributed to the death of a newborn, Zhu 
et al. recognize the immaturity of the neonate’s immune 
system with accompanying high viremia in the mother [41]. 
1 case of intrauterine fetal death has been reported.
Currently, there is no literature data available confirm-
ing the possibility of intrauterine vertical transmission. The 
most reliable evidence for intrauterine vertical transmission 
would be confirmation of SARS-CoV-2 replication in fetal 
lungs, which is technically not possible. Intrauterine viral 
infection is determined based on confirmation of the pres-
ence of the virus in samples of the placenta, amniotic fluid, 
umbilical cord blood and newborn throat swab. To avoid 
contamination of samples, they should be taken immedi-
ately after delivery using aseptic technique. The first study, 
which examined the possibility of intrauterine transmission 
of COVID-19 infection, was conducted by identification of 
SARS-CoV-2 in samples of amniotic fluid, umbilical cord 
blood and neonatal throat swabs using quantitative reverse 
transcriptase-polymerase (qRT-PCR) chain reaction in six 
pregnant women with confirmed COVID-19 infection and 
mild to moderate symptoms. Negative qRT-PCR results for 
SARS-CoV 2 RNA were recorded in all samples of the pla-
centa, amniotic fluid, umbilical cord blood and nasopharyn-
geal swabs, indicating that there was no intrauterine fetal 
infection in the third trimester of pregnancy [42].
Lei et al. [43] in a study of four pregnancies in which 
maternal COVID-19 infection was confirmed, also showed 
no evidence of the intrauterine vertical transmission in the 
third trimester.
In March this year, two reports were published de-
scribing three cases of newborns with elevated IgM an-
ti-SARS-CoV-2 titers in serological tests, even though the 
results of repeated nasopharynx swabs in qRT-PCR were 
negative [44, 45]. The reason for this could be, however, the 
susceptibility of IgM tests to false positive and false negative 
results, as well as the possible cross-reactions [46].
So far, only one case of positive qRT-PCR has been 
described in both mother and newborn [47]. The preg-
nant woman was admitted to the hospital with a fever 
at 40 weeks of pregnancy, the nasopharyngeal swab for 
SARS-CoV-2 qRT-PCR test was positive, thoracic comput-
erized tomography scan showed ground-glass opacities 
indicating bilateral interstitial pneumonia. A newborn was 
born by caesarean section in good condition. During the 
operation, the woman wore an N95 mask, the newborn 
had no contact with her after birth and was admitted to the 
Neonatology Department for observation. Despite the sta-
ble clinical status, the newborn had lymphocytopenia, liver 
dysfunction and elevated creatine kinase. A nasopharyngeal 
swab was taken from the newborn 36 hours after birth 
and came back positive. QRT-PCR results of umbilical cord 
blood and placenta samples were negative, but the possible 
transmission of SARS-CoV-2 from mother to child cannot 
be excluded. Both mother and child recovered and were 
discharged without any complications in good general 
condition [36].
Concerning ultrasound diagnostics during pregnancy, 
the Ultrasound Section of the Polish Society of Gynecolo-
gists and Obstetricians issued recommendations to mini-
mize the risk of SARS-CoV-2 transmission. These recom-
mendations include pre-selection of patients allowing 
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ultrasound examinations only for asymptomatic patients 
with a negative history.
In the case of patients with a negative epidemiological 
history, no fever, but with cold symptoms, it is advisable 
to postpone the examination until the symptoms resolve. 
Pregnant women with a positive interview should be quar-
antined for 14 days and postpone the ultrasound screen-
ing examinations. In case of emergency, hospital care in 
a dedicated hospital is recommended. Pregnant women 
with diagnosed COVID-19 or with a positive SARS-CoV-2 test 
should have ultrasound examinations performed only in 
case of justified medical indications in COVID-19 dedicated 
hospitals. In suspected or confirmed cases of COVID-19 in-
fection, ultrasound examination of fetal growth, amniotic 
fluid and umbilical artery blood flow should be performed 
when clinically necessary. Depending on the situation, these 
parameters should be monitored every 2–4 weeks. If COV-
ID-19 infection is confirmed during the first or early second 
trimester of pregnancy, an ultrasound examination should 
be performed between 18 and 24 weeks of pregnancy. In 
the case of outpatients, the first, second and third trimester 
scans should be performed, the remaining examinations 
should be postponed. Although the presence of virus RNA 
in the vaginal secretion has not been confirmed, due to 
the increased risk of virus transmission during a vaginal 
examination, the number of procedures performed with the 
vaginal transducer should be reduced, it is recommended to 
perform cervical length measurement by transabdominal 
examination [48].
According to the RCOG (Royal College of Obstetri-
cians and Gynaecologists) recommendations from 19 June 
2020 regarding the method of delivery in women with con-
firmed COVID-19 infection, there is no evidence indicating 
a specific way of delivery and it should be determined based 
on the obstetric situation and fetal well-being [49].
According to current recommendations of the National 
Consultant of Obstetrics and Gynecology, National Consult-
ant of Neonatology, National Consultant of Perinatology, 
Polish Society of Gynecologists and Obstetricians, Polish 
Society of Neonatology and the Polish Society of Perina-
tal Medicine, in the case of confirmed COVID-19 infection, 
caesarean section for epidemiological indications should 
be considered, except in situations where labor is advanced 
when neonate will be delivered within a short time. This 
recommendation aims to minimize the likelihood of infec-
tion of the newborn with a virus that may be found in the 
birth canal. The potential exposure to maternal excretions 
during caesarean section is incomparably lower compared 
to the vaginal delivery. Also, due to the potentially shorter 
duration of caesarean section compared to vaginal birth, 
the risk of intrauterine infection, especially after rupture of 
amniotic membranes and perinatal infection, is significantly 
reduced. The above recommendations also consider the risk 
of transmission to the medical personnel and aim to reduce 
the exposure time [50].
In case of pregnant women who underwent COV-
ID-19 without requiring admission to hospital, ended their 
isolation and are considered convalescents, there is no indi-
cation to modify the prior plans for the delivery [49].
In the case of anesthesia, there are no contraindications 
for the use of epidural or spinal anesthesia in the case of 
COVID-19 infection. If general anesthesia is required dur-
ing cesarean section, intubation is an infectious respiratory 
aerosol-generating procedure, which significantly increases 
the risk of medical personnel infection during surgery. How-
ever, there is no evidence indicating that aerosol particles 
would be generated by the inhalation of a mixture of nitrous 
oxide and oxygen (Entonox) [51].
There are discrepancies between the recommenda-
tions for umbilical cord clamping. Chinese guidelines, to 
reduce the risk of vertical transmission and to isolate the 
newborn from the infected mother as soon as possible, do 
not recommend delayed umbilical cord clamping [52]. The 
ISUOG (International Society of Ultrasound in Obstetrics and 
Gynecology) guidelines do not recommend umbilical cord 
clamping delay [53]. The RCOG guidelines take a different 
opinion, indicating that delayed umbilical cord clamping 
should be practiced, arguing that there is no significant 
increase in the risk of the infection transmission in the event 
of an additional minute of placental transfusion [49].
Regarding breastfeeding, Martins-Filho et al. reviewed 
the eight available publications regarding breastfeeding of 
24 symptomatic women infected with COVID-19. Biologi-
cal samples were taken immediately after delivery. Naso-
pharyngeal swabs in newborns and placental tissue samples 
showed negative results for the presence of SARS-CoV-2 in 
qRT-PCR. Also, all breastmilk samples of infected mothers 
were negative. However, given the small number of cases, 
these reports should be treated with extreme caution, be-
cause an additional significant risk factor for the infection of 
the newborn during breast-feeding is close contact between 
the woman and the child [54].
Due to the limited data, assessment of the risk of the 
transmission during lactation and determination whether 
standard pasteurization effectively eliminates the virus is 
not possible. In the cases of women suspected of infection, 
breastmilk should be drawn, pasteurized and, while follow-
ing aseptic principles, can then be given to the newborn. 
Breastmilk of women with confirmed infection should be 
utilized. However, lactation should not be suppressed in 
infected women if there is no medical indication so that 
when there is no risk of infection, they can feed naturally.
As far as the latest guidelines and the experts’ statement 
on COVID-19 infection is concerned, newborns should be 
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isolated from their mothers who have been infected until the 
risk of the infection stops [50]. There is no data available to 
determine the specific length of isolation and decisions about 
its end should be made individually as a result of discussions 
between the team of obstetricians and neonatologists [55].
RCOG in consultation with RCPCH (Royal College of 
Pediatrics and Child Health) advises against the routine 
separation of newborns from mothers with COVID-19 in-
fection [49].
According to the Centers for Disease Control and Preven-
tion (CDC), temporary separation of the newborn from the 
mother with suspected or confirmed COVID-19 should be 
considered to reduce the risk of transmission. The risks and 
benefits of temporary separation of mother and newborn 
should be discussed with the patient. Decisions regarding 
temporary separation should be made according to the 
wishes of the mother. If the mother decides to temporarily 
separate, to reduce the risk of spreading the virus and would 
like to breast-feed, she should obtain the breast milk with 
a breast pump. The obtained breast milk can be given to 
a newborn baby by a healthy caregiver.
If a mother with suspected or confirmed COVID-19 does 
not decide to be temporarily separated from the neonate in 
hospital, she should take precautions to avoid spreading the 
virus to the newborn, including proper hygiene and disin-
fection, keeping the right distance, using barrier protection 
equipment, using physical barriers, e.g. an incubator [56].
DISCUSSION
Pregnant women should use standard precautions, with 
emphasis on personal hygiene, frequent hand sanitizing, 
wearing face masks, and respect social distancing and iso-
lation.
Emphasis should be placed on routine screening for 
COVID-19 infection in pregnant women. Studies carried out 
so far show that infection in this group is usually asympto-
matic or mildly symptomatic and the screening strategy 
allows detection of infection cases in pregnant women. 
Although some of the asymptomatic pregnant women de-
veloped symptoms, the severity of the disease in pregnant 
women appears to be similar to the general population 
(mild — 86%; severe — 9.3%, critical — 4.7%).
Thanks to the strategy of universal screening of pregnant 
women, it is possible to identify a subgroup of asymptomatic 
women at the beginning or throughout the infection pe-
riod, who have limited access to the tests. These women 
are currently an under-represented group in population 
studies [57].
Despite the constantly increasing number of publica-
tions on COVID-19 infection in pregnancy, we still do not 
have sufficient data to be able to draw unequivocal conclu-
sions about the course of infection in pregnant women, 
effects on foetal development, maternal and neonatal out-
comes, as well as vertical transmission.
Therefore, an immensely important issue is the need 
for systematic reporting of data on women affected by 
COVID-19 and the course of these pregnancies, considering 
the maternal and neonatal outcomes [26]. Over time, this 
will help to create the recommendations and guidelines 
that will ensure an adequate level of care for a patient af-
fected by COVID-19 infection during pregnancy, delivery 
and postpartum period as well as improvement of the medi-
cal personnel protection.
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